– CANADA, Winnipeg – Kane Biotech Inc. (TSX:KNE | OTC:KNBIF) today announced the appointment of Rivka Gluck to its Board of Directors.
With over 20 years of experience in the global pharmaceutical, biotechnology, and life science industries, Ms. Gluck’s career has spanned all levels and functions in clinical development. As an executive, her focus has been on leading the strategic planning and successful implementation of high-quality clinical development programs.
Ms. Gluck’s leadership in the life sciences industry spans both publicly-traded and private companies. Currently, Ms. Gluck is on the executive management team of Aurinia Pharmaceuticals, developing and implementing their overall corporate strategy. She also leads all clinical operations for their lead drug, voclosporin. Prior to that, Ms. Gluck has held management-level, clinical operations roles at innovative companies including Qu Biologics, Vifor Pharma, Novartis, and GlaxoSmithKline, among others.
“We are proud to appoint Rashieda to our Board of Directors, bringing her wealth of experience in overseeing and effectively running clinical operations in many environments. She is ideally suited to help guide Kane Biotech at this time with the number of clinical and efficacy studies we currently have ongoing for multiple pet and human health-related conditions. Her clinical development knowledge, as well as her ability to run efficient programs and her versatility in multiple aspects of healthcare and life sciences, is a solid strategic match for the broad applicability of our biofilm-preventing technologies.” said CEO, Mark Ahrens-Townsend.
About Rivka Gluck
Ms. Gluck currently serves as SVP of Global Clinical Operations at Aurinia Pharmaceuticals Inc. since February 2018 and has also served as its VP, Clinical Operations since January 1, 2016. She previously served as VP, Clinical Operations at Qu Biologics Inc., and was responsible for leading their clinical programs and providing strategic direction for the clinical development of their platform immunotherapeutic treatments in multiple disease indications. Prior to that, Ms. Gluck served as VP, Clinical Operations at Aspreva in New Jersey, and was responsible for the successful integration of the global clinical operations department post-acquisition by Zurich-based Vifor Pharmaceuticals. At Vifor, she served as VP and Head of Global Clinical Operations where she was a member of the Research, Development, and Leadership team and continued to build and lead the clinical research department in Zurich and hold overall accountability for the execution and delivery of all global clinical programs. In her career, Ms. Gluck served in increasingly senior positions at major pharmaceutical companies including Novartis, Organon, and GSK.
Ms. Gluck holds a B.Sc. in Nursing from the University of British Columbia.
About Kane Biotech
Kane Biotech is a biotechnology company engaged in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms.
The Corporation has a portfolio of biotechnologies, intellectual property (75 patents and patents pending, trade secrets, and trademarks) and products developed by the Corporation’s own biofilm research expertise and acquired from leading research institutions. StrixNB, DispersinB, Aledex, bluestem, AloSera, coactiv+, and Kane are trademarks of Kane Biotech Inc.
For more information: http://www.kanebiotech.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
